4-氯-2-乙基噻吩并[2,3-d]嘧啶 | 56844-11-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: 4-氯-2-乙基噻吩并[2,3-d]嘧啶
• 中文别名: 4-氯-2-乙基噻吩并[2,3-D]嘧啶
• 英文名称: 4-chloro-2-ethyl-thieno[2,3-d]pyrimidine
• 英文别名: 4-Chloro-2-ethylthieno[2,3-d]pyrimidine
• CAS: 56844-11-2
• 化学式: C₈H₇ClN₂S
• mdl: MFCD16250488
• 分子量: 198.676
• InChiKey: PKCDEKLEICRQKQ-UHFFFAOYSA-N

物化性质

• 沸点：
  228℃
• 密度：
  1.377
• 闪点：
  92℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2至8°C，惰性气体

反应信息

• 作为反应物：
  描述：

  4-氯-2-乙基噻吩并[2,3-d]嘧啶 在 一水合肼 作用下， 生成 2-ethyl-4-hydrazino-thieno[2,3-d]pyrimidine
  参考文献：
  名称：

  Robba,M. et al., Bulletin de la Societe Chimique de France, 1975, p. 592 - 597

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基噻吩-3-羧酸甲酯 在 盐酸 、 三氯氧磷 作用下， 以 1,4-二氧六环 为溶剂， 反应 6.25h， 生成 4-氯-2-乙基噻吩并[2,3-d]嘧啶
  参考文献：
  名称：

  [EN] THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS
  [FR] THIÉNO[2,3-D]PYRIMIDINES ET BENZOFURO(3,2-D) PYRIMIDINES UTILES EN TANT QU'AGENTS ANTIMICROBIENS

  摘要：

  本公开提供了可用于治疗结核病的化合物、方法和组合物。在某些实施例中，这些化合物和组合物具有对结核分枝杆菌（Mtb）具有杀菌作用的特性。还提供了使用这些药剂的方法。

  公开号：

  WO2019018359A1

文献信息

• [EN] COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DE LA TUBERCULOSE
  申请人：FIMBRION THERAPEUTICS INC

  公开号：WO2022236182A1

  公开（公告）日：2022-11-10

  The present disclosure relates to various compounds and compositions which are useful for the treatment of tuberculosis and other diseases such as infections caused byMycobacterium tuberculosis. The present disclosure also relates to various methods of using these compounds and compositions to treat tuberculosis and other diseases such as infections caused byMycobacterium tuberculosis. Further, the present disclosure relates to processes of preparing these compounds and compositions.

  本公开涉及各种化合物和组合物，这些化合物和组合物对于治疗结核病和其他疾病（如由结核分枝杆菌引起的感染）非常有用。本公开还涉及使用这些化合物和组合物治疗结核病和其他疾病（如由结核分枝杆菌引起的感染）的各种方法。此外，本公开还涉及制备这些化合物和组合物的过程。
• Discovery of the selective and efficacious inhibitors of FLT3 mutations
  作者：Yanle Zhi、Baoquan Li、Chao Yao、Hongmei Li、Puzhou Chen、Jiyin Bao、Tianren Qin、Yue Wang、Tao Lu、Shuai Lu

  DOI：10.1016/j.ejmech.2018.06.010

  日期：2018.7

  Fms-like tyrosine kinase 3 (FLT3) is among the most frequently mutated protein in acute myeloid leukemia (AML), which has been confirmed as an important drug target for AML chemotherapy. Starting from the lead compound LT-106-175, a series of 1-H-pyrazole-3-carboxamide derivatives were synthesized to improve the FLT3 inhibitory potency and selectivity. Among them, compound 50 was identified as a highly potent and selective FLT3 inhibitor (IC50 = 0.213 nM), which showed equal activities against various mutants of FLT3 including FLT3 (ITD)-D835V and FLT3 (ITD)-F691L that is resistant to quizartinib. Compound 50 also exhibited efficacy against the human AML cell line MV4-11 (IC50 = 16.1 nM) harboring FLT3-ITD mutants. Inversely, compound 50 displayed no cytotoxicity to FLT3-independent cells, and the biochemical analyses showed that its effects were related to the inhibition of FLT3 signal pathways. Additionally, compound 50 induced apoptosis in MV4-11 cell as demonstrated by flow cytometry. Moreover, compound 50 showed enhanced metabolic stability. Altogether, it was concluded that compound 50 could be a promising FLT3 inhibitor for further developing therapeutic remedy of AML (C) 2018 Elsevier Masson SAS. All rights reserved.
• ROBBA M.; LECOMTE J.-M.; CUGNON DE SEVRICOURT M., BULL. SOC. CHIM. FRANCE <BSCF-AS>, 1975, NO 3-4, PART. 2, 592-597
  作者：ROBBA M.、 LECOMTE J.-M.、 CUGNON DE SEVRICOURT M.

  DOI：——

  日期：——
• THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS
  申请人：Saint Louis University

  公开号：US20220117968A1

  公开（公告）日：2022-04-21

  The present disclosure provides compounds, methods, and compositions which may be used to treat tuberculosis. In some embodiments, these compounds and compositions have a bactericidal property against Mycobacterium tuberculosis (Mtb). Methods of employing such agents are also provided.
• [EN] THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS<br/>[FR] THIÉNO[2,3-D]PYRIMIDINES ET BENZOFURO(3,2-D) PYRIMIDINES UTILES EN TANT QU'AGENTS ANTIMICROBIENS
  申请人：UNIV SAINT LOUIS

  公开号：WO2019018359A1

  公开（公告）日：2019-01-24

  The present disclosure provides compounds, methods, and compositions which may be used to treat tuberculosis. In some embodiments, these compounds and compositions have a bactericidal property against Mycobacterium tuberculosis (Mtb). Methods of employing such agents are also provided.

  本公开提供了可用于治疗结核病的化合物、方法和组合物。在某些实施例中，这些化合物和组合物具有对结核分枝杆菌（Mtb）具有杀菌作用的特性。还提供了使用这些药剂的方法。